Internal Medicine, Rheumatology · Salisbury, NC
NPI
1295712305
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
611 Mocksville Ave
Salisbury, NC, 28144
Phone (704) 633-7220
Groups this clinician bills Medicare through
Medicare paid, 2024
$893K
70,300 services
Medicare patients, 2024
172
Average age 73
Drug cost, 2024
$3.7M
4,213 prescriptions
Company payments, 2025
$3,114
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rakesh C Patel was code J3262 (injection, tocilizumab, 1 mg), 39,734 times for 12 patients. In total Rakesh C Patel billed 70,300 services in 40 codes, and Medicare paid $893K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 39,734 | 12 | $4.68 | $186K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 14,501 | 21 | $33.83 | $491K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 8,852 | 12 | $9.04 | $80K |
| J0897 Injection, denosumab, 1 mg | Office | 1,202 | 13 | $20.45 | $25K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 727 | 16 | $0.11 | $76.44 |
| 99214 Office E&M - Established | Office | 403 | 146 | $86.72 | $35K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 318 | 39 | $0.51 | $163 |
| 96413 Chemotherapy Administration | Office | 307 | 38 | $93.25 | $29K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 211 | 114 | $11.34 | $2,394 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 159 | 28 | $0.61 | $96.55 |
| 96372 Injection Administration | Office | 111 | 50 | $10.35 | $1,149 |
| 99215 Office E&M - Established | Office | 89 | 64 | $113.62 | $10K |
| 76882 Ultrasound - Nonspecific | Office | 28 | 15 | $45.23 | $1,266 |
| 20610 Joint Injection | Office | 23 | 13 | $47.97 | $1,103 |
| 99204 Office E&M - New | Office | 22 | 22 | $119.03 | $2,619 |
By year: 2022 $1.3M for 69,961 services; 2023 $1.3M for 62,660 services; 2024 $893K for 70,300 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rakesh C Patel prescribed most often to Medicare patients was Prednisone, with 917 prescriptions and refills. In total Rakesh C Patel wrote 4,213 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 917 | 1,279 | 217 | $3,352 |
| Hydroxychloroquine Sulfate Generic | 870 | 1,531 | 200 | $13K |
| Methotrexate Methotrexate Sodium | 566 | 1,081 | 140 | $6,981 |
| Enbrel Mini Etanercept | 188 | 188 | 25 | $1.4M |
| Mycophenolate Mofetil Generic | 148 | 202 | 32 | $6,327 |
| Diclofenac Sodium Generic | 108 | 112 | 47 | $14K |
| Rinvoq Upadacitinib | 100 | 108 | 16 | $690K |
| Cyclobenzaprine Hcl Generic | 91 | 121 | 25 | $419 |
| Colchicine Generic | 90 | 141 | 24 | $6,731 |
| Meloxicam Generic | 83 | 118 | 18 | $249 |
| Folic Acid Generic | 74 | 148 | 19 | $462 |
| Kevzara Sarilumab | 73 | 73 | 12 | $309K |
| Allopurinol Generic | 64 | 117 | 19 | $396 |
| Febuxostat Generic | 61 | 92 | Under 11 | $4,672 |
| Orencia Clickject Abatacept | 50 | 50 | Under 11 | $280K |
Brand drugs: 689 claims; generic drugs: 3,524 claims; opioid claims: 13.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rakesh C Patel $3,114 ($3,004 in general payments such as food, travel and fees and $110 for research) from 19 companies. The largest payer was Amgen Inc. with $587.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 43 | $587 |
| UCB, Inc. UCB.BR | 12 | $315 |
| Abbvie Inc. ABBV | 16 | $265 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $248 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $243 |
| E.R. Squibb & Sons, L.L.C. BMY | 12 | $239 |
| ANI Pharmaceuticals, Inc. ANIP | 9 | $194 |
| Janssen Biotech, Inc. JNJ | 10 | $166 |
| Mallinckrodt Hospital Products Inc. | 10 | $163 |
| GlaxoSmithKline, LLC. GSK | 6 | $155 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.